Synergetics USA to Be Acquired by Valeant Pharmaceuticals
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
Go back to Synergetics USA to Be Acquired by Valeant Pharmaceuticals
September 3, 2015 8:27 AM EDT
Stephens downgraded Synergetics USA (NASDAQ: SURG) from Overweight to Equal Weight.
For an analyst ratings summary and ratings history on Synergetics USA click here. For more ratings news on Synergetics USA click here.
Shares of Synergetics USA closed at $6.58 yesterday.
...
More
September 2, 2015 10:23 AM EDT
BMO Capital reiterated an Outperform rating and $285.00 price target on Valeant Pharmaceuticals (NYSE: VRX) following the company's announced agreement to buy Synergetics USA (NASDAQ: SURG). Analyst Alex Arfaei said that although this is a small... More
September 2, 2015 8:02 AM EDT
Synergetics USA, Inc. (NASDAQ: SURG) and Valeant Pharmaceuticals International ("Valeant"), a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX), announced that they have entered into a definitive agreement under which Valeant will acquire Synergetics for $6.50 per share in cash. In addition to the upfront cash payment, Synergetics stockholders will receive additional cash payments of up to $1.00 per share if specified sales milestones are achieved following the closing. The transaction is expected to close in the fourth quarter of 2015 and is subject to customary closing conditions and regulatory approvals.
The... More
